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LETTER TO THE EDITOR
Proficiency Testing for
Meropenem and
Piperacillin Therapeutic
Drug Monitoring:
Preliminary Results
From the Belgian
Society on Infectiology
and Clinical
Microbiology
Pharmacokinetic–
Pharmacodynamic
Working Group
To the Editor:
Infection is a well-recognized but
persisting problem in critically ill pa-
tients with high mortality and morbid-
ity.1 Timely and appropriate antibiotic
therapy after source control is consid-
ered to be the mainstay of treatment.
Achieving adequate antibiotic exposure
may also be important, as shown by
a recent point prevalence study, suggest-
ing a correlation between plasma con-
centrations of the antibiotics and
outcome.2 b-lactam antibiotics are most
commonly used because of their favor-
able safety proﬁle and broad spectrum of
activity.3 Optimizing antibiotic exposure
is proving to be a great challenge with
recent data showing that the antibiotic
concentrations in critically ill patients
are highly variable, unpredictable, and
commonly suboptimal,2,4–6 not only
between patients but also within the
same patient.7
Although there is currently no
evidence that therapeutic drug monitor-
ing (TDM) leads to improved clinical
outcomes, it is gaining popularity as
a means to individualize antibiotic
dosing in difﬁcult patient populations
such as the critically ill.8–11 TDM of
b-lactam antibiotics has also been rec-
ommended in a recently published
guideline by a multidisciplinary expert
panel as a strategy to improve antibiotic
therapy in intensive care units.12 There-
fore, several laboratories developed
b-lactam assays. These methods
undergo an in-house validation, cover-
ing accuracy, precision, selectivity,
matrix effect, and stability. Although
these validations are properly performed
and based on international guidelines,
the lack of a commercially available
control or calibration material remains
a major hurdle.13 To test the concor-
dance of these laboratory-developed
tests, we performed an interlaboratory
proﬁciency testing program for the mea-
surement of meropenem and piperacil-
lin. In this report, we describe the
results of this round robin test.
In 2015, we sent 2 sets of 8
meropenem and 2 sets of 8 piperacillin
samples on dry ice to the 9 participating
laboratories in Belgium. Each set con-
tained 3 spiked samples (bovine serum
spiked with a low, medium, and high
concentration) and 5 patient pool sam-
ples (low, medium, and high) from
patients treated with the antibiotic.
These sets included identical samples
to be able to calculate a consensus mean
and to calculate intralaboratory variabil-
ity. The concentrations of the samples
were in the range of concentrations
expected in patients treated with these
antibiotics. All participating laboratories
were provided feedback on their results.
The accuracy of a result was acceptable
if the reported concentration was within
the 80%–120% limits of the consensus
mean. This 80%–120% threshold is
based on guidelines for method valida-
tion where a ﬁxed criterion for inaccur-
acy of 20% at the lowest level of
quantiﬁcation is commonly used.14,15
The details on the preparation of the
quality control, the patient samples,
and the calculation of the consensus
mean are provided in the Supplemental
Digital Content 1 (http://links.lww.
com/TDM/A218) and Supplemental
Digital Content 2 and 3 (see Supple-
mentary Tables 1 and 2, http://links.
lww.com/TDM/A215, http://links.lww.
com/TDM/A216, respectively).
All 9 participating laboratories
analyzed the meropenem samples. Three
of the 9 participating centers only per-
form this analysis for study purposes.
One center is still in the validation phase
and 5 centers perform it on a routine
basis. More details on the laboratories
performing this analysis as part of the
routine are summarized in Table 1.
Two laboratories did not have an
assay for piperacillin available and 1
laboratory failed to send in their results
for piperacillin. Therefore, the results of
only 6 laboratories on the samples con-
taining piperacillin are reported. Most
participants (n = 6/9 for meropenem
and n = 4/6 for piperacillin) used liquid
chromatography with an ultraviolet
detector. The other centers used liquid
chromatography with mass spectrometry
detection to determine the concentrations.
Details on the methods used can be found
in the Supplemental Digital Content 4,
(see Supplementary Table 3, http://
links.lww.com/TDM/A217).
A quantitative result was obtained
for 93% (n = 134/144) of the samples for
meropenem (technical accident for 8
samples, 2 samples with a concentration
, lower limit of quantiﬁcation). For
meropenem, the results of 2 laboratories
were excluded from the calculation of
the consensus mean because the mean
reported concentration of 2/3 spiked
samples deviated .50% from the
weighed-in concentration. The results
are shown in Figures 1A, B. Only 57%
of the results for meropenem were
within the predeﬁned accuracy limits
(77/134). For piperacillin, a quantitative
result was obtained for 86/96 samples
(9 samples , lower limit of quantiﬁca-
tion), and only 72% of the results were
within accuracy limits (63/87).
The percentage of accurate results
per laboratory ranged between 0% and
94% for meropenem (median 63%) and
between 6% and 100% (median 72%)
for piperacillin. Five of the 9 laborato-
ries determining meropenem had #2
samples within the 80%–120% limits
of the consensus mean. One center re-
ported all meropenem samples inaccu-
rately and another center reported all
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but 1 sample inaccurately. These results
are summarized in Supplemental Digi-
tal Content 3 and 4, (see Supplemen-
tary Tables 2 and 3, http://links.lww.
com/TDM/A216, http://links.lww.com/
TDM/A217, respectively).
This small study shows that 43%
of the meropenem and 28% of the
piperacillin samples were measured
inaccurately. It is unclear what factors
caused the observed variability. Usage
of in-house prepared calibration material
from different sources may be an impor-
tant factor, but the limited stability of
these antibiotics might also add to the
observed variability. Our ﬁndings are in
line with data from similar quality
control programs, such as Asqualab
(Assurance qualité des laboratories de
biologie médicale), a French association
of clinical chemists that organizes qual-
ity control programs. The results of this
quality control program on specialized
antibiotics (which also includes pipera-
cillin) also showed a very wide variabil-
ity among laboratories (results of EEQ
1865A received by our laboratory).
These ﬁndings are clinically relevant
because inaccurate results may result in
incorrect dose adjustments in TDM and
TABLE 1. Participating Laboratories
Laboratory No. of Runs per Week No. of Samples per Year Indication for TDM Preanalytical Instructions
1 1 (analysis the next day if urgent) 120 Special cases* Rapid transportation of the blood
sample to the laboratory. Storage
of plasma at 220°C until analysis
2 3 100 Special cases* Transport of the blood sample at 4°
C. Storage of plasma at 220°C
until analysis
3 On request 50 Special cases* Transport of the blood sample in
a container with ice. Storage of
plasma at 280°C
4 2 50 Special cases* Transport of the blood sample in
a container with ice. Storage of
plasma at 220°C
5 5 1400 All patients in the intensive care unit
+ special cases*
Transport of the blood sample in
a container with ice. Storage of
plasma at 280°C
*Special cases such as clinical failure, augmented renal clearance, treatment of a resistant isolate infection, and extracorporeal circuits.
FIGURE 1. A, Mean meropenem concentration per laboratory.
B, Mean piperacillin concentration per laboratory.
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potentially lead to treatment failure or
unnecessary toxicity.
The results of the ﬁrst round of
this interlaboratory proﬁciency testing
program therefore demonstrates the need
for an ongoing proﬁciency testing
program to improve these assays.
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